drugset / Trial / NCT04457687

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

NCT04457687

Expanded access Available Eisai Inc.

Summary

The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorcaserin Small molecule 10 mg Oral

Indications